Protagonist Therapeutics, Inc

For the period ended Jun 30, 2025. Filed Aug 6, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Aug 6, 2025

PTGX$135.90+2.9%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations

(In thousands, except share and per share data)


· · Three Months Ended · · Six Months Ended
· · June 30, · · June 30,
· 2025 · 2024 · 2025 · 2024
License and collaboration revenue	$5,546	$4,167	$33,867	$259,120
Operating expenses:
Research and development	37,036	33,520	72,929	67,254
General and administrative	10,551	9,440	22,289	24,350
Total operating expenses	47,587	42,960	95,218	91,604
(Loss) income from operations	(42,041)	(38,793)	(61,351)	167,516
Interest income	7,406	7,404	14,979	11,780
Other income, net	36	97	118	78
(Loss) income before income tax expense (benefit)	(34,599)	(31,292)	(46,254)	179,374
Income tax expense (benefit)	172	(676)	172	2,650
Net (loss) income	$(34,771)	$(30,616)	$(46,426)	$176,724
Net (loss) income per share, basic	$(0.55)	$(0.50)	$(0.73)	$2.89
Net (loss) income per share, diluted	$(0.55)	$(0.50)	$(0.73)	$2.77
Weighted-average shares used to compute net (loss) income per share, basic	63,510,537	61,305,289	63,238,682	61,080,489
Weighted-average shares used to compute net (loss) income per share, diluted	63,510,537	61,305,289	63,238,682	63,909,633

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.